Tommy was diagnosed with bladder cancer just before his 60th birthday. Now, thanks to a Cancer Research UK trial, he’s enjoying playing ...

Among patients with low-grade, intermediate-risk NMIBC, UGN-102 generated robust, durable responses in an analysis of the ...

Researchers led by the University of Ulsan College of Medicine, Korea, have checked the performance of a noninvasive urinary ...

Among patients with suspected MIBC, the incorporation of mpMRI for initial staging prior to transurethral resection of ...

The bladder cancer market is poised for transformative growth between 2025 and 2035, driven by rising global incidence rates, ...

The Bladder Cancer Company, announces the presentation on February 14 of a new abstract with study results from its U.S.

American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 13 th and 15 th 2025, was host to the Panning for Gold: The Role of ctDNA as ...

Exploratory outcome measures include health-related quality of life, overall survival, and biomarker assessments. A broad cross-section of geographically and socioeconomically diverse clinical sites ...

Recent study results show that the single-target DNA methylation test performed with a negative predictive value of 97.6 percent.

Recent study results show that the single-target DNA methylation test performed with a negative predictive value of 97.6 percent.